Products Categories
CAS No.: | 27164-46-1 |
---|---|
Name: | Cefazolin sodium salt |
Article Data: | 6 |
Molecular Structure: | |
Formula: | C14H14N8O4S3. Na |
Molecular Weight: | 476.496 |
Synonyms: | 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-,monosodium salt, (6R,7R)- (9CI);5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-,monosodium salt (8CI);3-[[(5-Methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[2-(1H-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid sodium salt;Acef;Ancef;Atirin;Biazolina;Bor-Cefazol;Cefacidal;Cefazil;Cefazoliin;Cefazolin sodium;Cefazoline sodium;Cephazolin sodium;Cephazolin sodiumsalt;Firmacef;Gramaxin;Kefzol;Lampocef;Liviclina;Monosodium cafazolin;Reflin;SKF 41558;Sodium cefazolin;Sodium cephazolin;Totacef;Zolicef;Cefazolin sodium salt; |
EINECS: | 248-278-4 |
Melting Point: | 190 °C |
Solubility: | 50 mg/mL in water |
Appearance: | White to off-white powder |
Hazard Symbols: | Xi, Xn |
Risk Codes: | 20/21/22-36/37/38-42/43 |
Safety: | 22-36/37 |
PSA: | 237.76000 |
LogP: | -1.64200 |
What can I do for you?
Get Best Price
1. Introduction of Cefazolin sodium salt
Cefazolin sodium salt is one kind of white or almost white powder. For being a kind of white to off-white powder, it is stable chemically but is incompatible with strong oxidizing agents. The IUPAC name of it is sodium 3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate. In addition, its product categories are including Active Pharmaceutical Ingredients; API; Antibiotics for Research and Experimental Use; beta-Lactams (Antibiotics for Research and Experimental Use); Biochemistry; Antibiotic Explorer; Intermediates & Fine Chemicals; Pharmaceuticals; Sulfur & Selenium Compounds; A - KResearch Essentials. The Classification Code of it is Antibacterial [systemic]; Antibiotics; Drug / Therapeutic Agent; Human Data; Reproductive Effect.
2. Properties of Cefazolin sodium salt
Physical properties about Cefazolin sodium salt are:
(1)ACD/LogP: 1.13; (2)# of Rule of 5 Violations: 1; (3)#H bond acceptors: 12; (4)#H bond donors: 2; (5)#Freely Rotating Bonds: 7; (6)Polar Surface Area: 226.14; (7)Exact Mass: 476.011958; (8)MonoIsotopic Mass: 476.011958.
3. Structure Descriptors of Cefazolin sodium salt
(1)Canonical SMILES: CC1=NN=C(S1)SCC2=C(N3C(C(C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)[O-].[Na+]
(2)InChI: InChI=1S/C14H14N8O4S3.Na/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21;/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26);/q;+1/p-1
(3)InChIKey: FLKYBGKDCCEQQM-UHFFFAOYSA-M
4. Toxicity of Cefazolin sodium salt
Below are the toxicity information of this chemical:
Organism | Test Type | Route | Reported Dose (Normalized Dose) | Effect | Source |
---|---|---|---|---|---|
dog | LD50 | intravenous | 2200mg/kg (2200mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 29, Pg. 424, 1979. | |
dog | LD50 | subcutaneous | 4gm/kg (4000mg/kg) | GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: NAUSEA OR VOMITING | Chemotherapy Vol. 18, Pg. 528, 1970. |
human | TDLo | intramuscular | 14mg/kg/D (14mg/kg) | GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS GASTROINTESTINAL: NAUSEA OR VOMITING SKIN AND APPENDAGES (SKIN): "DERMATITIS, ALLERGIC: AFTER SYSTEMIC EXPOSURE" | Japan Medical Gazette. Vol. 8(8), Pg. 10, 1971. |
mouse | LD50 | intraperitoneal | 6200mg/kg (6200mg/kg) | Drugs in Japan Vol. 6, Pg. 404, 1982. | |
mouse | LD50 | intravenous | 3900mg/kg (3900mg/kg) | Journal of Infectious Diseases. Vol. 128, Pg. S379, 1973. | |
mouse | LD50 | oral | > 11gm/kg (11000mg/kg) | Chemotherapy Vol. 18, Pg. 528, 1970. | |
mouse | LD50 | subcutaneous | 7600mg/kg (7600mg/kg) | Journal of Infectious Diseases. Vol. 128, Pg. S379, 1973. | |
rabbit | LD50 | intravenous | 2500mg/kg (2500mg/kg) | Arzneimittel-Forschung. Drug Research. Vol. 29, Pg. 424, 1979. | |
rabbit | LD50 | subcutaneous | > 6gm/kg (6000mg/kg) | Chemotherapy Vol. 18, Pg. 528, 1970. | |
rat | LD50 | intraperitoneal | 7400mg/kg (7400mg/kg) | Drugs in Japan Vol. 6, Pg. 404, 1982. | |
rat | LD50 | intravenous | 2760mg/kg (2760mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA | Chemotherapy Vol. 35(Suppl, |
rat | LD50 | oral | > 11gm/kg (11000mg/kg) | Chemotherapy Vol. 18, Pg. 528, 1970. | |
rat | LD50 | subcutaneous | 10gm/kg (10000mg/kg) | BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" | Japan Medical Gazette. Vol. 8(8), Pg. 10, 1971. |
women | TDLo | intravenous | 660mg/kg/11D- (660mg/kg) | BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD | Nephron. Vol. 45, Pg. 72, 1987. |